Articles
Ribba B, Watkin E, Tod M, Girard P, Grenier E, You B, Giraudo E, Freyer G. A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. Eur J Cancer In Press. Abstract ICI
Bouillon-Pichault M, Jullien V, Bazzoli C, Pons G, Tod M. Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4. J Pharmacokinet Pharmacodyn In Press. Abstact ICI
You B, Le Tourneau C, Chen X E, Wand L, Jarvi A, Bharadwaj R R, Kamel-Reid S, Perez-Ordonez B, Mann Vijay, Siu L L. A phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or meRibba B, Watkin E, Tod M, Girard P, Grenier E, You B, Giraudo E, Freyer G. A model of vascular tumour growth in mice combining longitudinal tumor size with histological biomarkers. Eur J Cancer In Press. Abstract ICItastatic nasopharyngeal carcinoma. Am J Clin Oncol In Press.
You B, Chen X E. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab. J Clin Pharmacol In Press.
Basanta D, Ribba B, Watkin E, You B, Deutsch A. Computational analysis of the influence of microenvironment on carcinogenesis. Mathematical Biosciences In Press. Abstract ICI
You B, Brade A, Magalhaes JM, Siu LL, Oza A, Lovell S, et al. A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Invest New Drugs 2010 In Press. Abstract ICI
Gérard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M. Influence of Dosing Schedule on Organ Exposure to Cyclosporin in Pediatric Hematopoietic Stem Cell Transplantation: Analysis with a PBPK Model. Pharm Res. 2010 Sep 2 In Press. Abstract ICI
Gérard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M. Links Between Cyclosporin Exposure in Tissues and Graft-Versus-Host Disease in Pediatric Bone Marrow Transplantation: Analysis by a PBPK Model. Pharm Res. 2010 In Press. Abstract ICI
Cotte E, Colomban O, Guitton J, Tranchand B, Bakrin N, Gilly FN, Glehen O, Tod M. Population Pharmacokinetics and Pharmacodynamics of Cisplatinum During Hyperthermic Intraperitoneal Chemotherapy Using a Closed Abdominal Procedure. J Clin Pharmacol. 2010 Feb 19 In Press. Abstract ICI
Freyer G, Hernández-Sánchez J, Vukasinovic N. Effect of family relatedness on characteristics of estimated IBD probabilities in relation to precision of QTL estimates. BMC Genet 2010 Sep 26;11:85. Abstract ICI
Falandry C, Campone M, Cartron G, Guerin D, Freyer G. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer. 2010 Sep;46(13):2389-2398. Abstract ICI
You B, Fronton L, Boyle H, Droz JP, Girard P, Tranchand B, Ribba B, Tod M, Chabaud S, Coquelin H, Fléchon A. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor. Urology. 2010 Aug;76(2):423-429. Abstract ICI
You B, Pollet-Villard M, Fronton L, Labrousse C, Schott AM, Hajri T, Girard P, Freyer G, Tod M, Tranchand B, Colomban O, Ribba B, Raudrant D, Massardier J, Chabaud S, Golfier F. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol. 2010 Aug;21(8):1643-1650. Abstract ICI
Steimer Jl, Dahl Sg, De Alwis Dp, Gundert-Remy U, Karlsson Mo, Martinkova J, Aarons L, Ahr Hj, Clairambault J, Freyer G, Friberg Le, Kern Se, Kopp-Schneider A, Ludwig Wd, De Nicolao G, Rocchetti M, Troconiz I. Modelling the genesis and treatment of cancer: the potential role of physiologically base pharmacodynamics. Eur J Cancer 2010 Jan; 46(1):21-32. Abstract ICI
Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol. 2010 Mar;65(4):755-763. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Gérard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M. Influence of cyclosporin dosing schedule on receptor occupancy in bone marrow transplantation: analysis with a PBPK-PD model. PAGE 19 (2010) Abstr 1924
Colomban O, Naudet B, Maucort-Boulch, Roy, Girard P. Toxicogenomic dose-response models for DNA chips data from rats treated by flutamide. PAGE 19 (2010) Abstr 1854
Paule I, Girard P, Tod M. Estimation of Individual Parameters of a Mixed–Effects Dose-Toxicity Model for Ordinal Data. PAGE 19 (2010) Abstr 1785
Ribba B,, Watkin E, Tod M, Girard P, Grenier E, You B, Wei M, Giraudo E, Freyer G. Combined analysis of tumor size data and histological biomarkers drives the development of a semi-mechanistic model of the effect of the antiangiogenic drug Sunitinib in mice. PAGE 19 (2010) Abstr 1801
Sostelly A, Payen L, Ribba B, Di Pietro A, Falson P, Girard P, Tod M. Modelling the interaction between Irinotecan and efflux transporters inhibitors: A KPD tumour growth inhibition model including interaction components. PAGE 19 (2010) Abstr 1706
Abstracts ASCO (American Society of Clinical Oncology)
Boudou-Rouquette P, Blanchet B, Mir O, Billemont B, Ropert S, Barete S, Coriat R, Franck N, Tod M, Goldwasser F. Proposal of a new population pharmacokinetic model of sorafenib and rationale for a three daily schedule. 2010 ASCO Annual Meeting. J Clin Oncol ASCO Annual Meeting Proceedings;2010 28:15s, suppl; abstr 3044.
Articles
D Ternant, E Hénin, G Cartron, M Tod, G Paintaud, P Girard. Development of a drug by disease simulation model for rituximab in follicular non-Hodgkin lymphoma. Br J Clin Pharmacol. 2009 oct;68(4):561-573. Abstract ICI
Hénin E, Tod M, Trillet-Lenoir V, Rioufol C, Tranchand B, Girard P. Pharmacokinetically Based Estimation of Patient Compliance with Oral Anticancer Chemotherapies: In Silico Evaluation. Clin Pharmacokinet 2009 Jun 6;48(6):359-369. Abstract ICI
Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, Fagerberg J, Bruno R. Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics. J Clin Oncol 2009 Sep 1;27(25):4103-4108. Abstract ICI
Falandry C, Canney PA, Freyer G, Dirix LY. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 2009 Apr;20(4):615-20. Abstract ICI
Falandry C, Debled M, Bachelot T, Delozier T, Crétin J, Romestaing P, Mille D, You B, Mauriac L, Pujade-Lauraine E, Freyer G. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat 2009 Aug;116(3):501-508. Abstract ICI
You B, Girard P, Paparel P, Freyer G, Ruffion A, Charrié A, Hénin E, Tod M, Perrin P. Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy. Prostate. 2009 Sep 1;69(12):1325-1333. Abstract ICI
Hénin E, You B, Vancutsem E, Hoff P, Cassidy J, Twelves C, Zuideveld K, Sirzen F, Dartois C, Freyer G, Tod M, Girard P. A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving Capecitabine. Clin Pharmacol Ther 2009;85:418-425. Abstract ICI
Ribba B, You B, Tod M, Girard P, Tranchand B, Trillet-Lenoir V, Freyer G. Chemotherapy may be delivered based on an integrated view of tumour dynamics. IET Syst Biol 2009;3:180-190. Abstract ICI
Delavenne X, Laporte S, Demasles S, Mallouk N, Basset T, Tod M, Girard P, Mismetti P. Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid. Fundam Clin Pharmacol. 2009 Feb;23(1):127-135. Abstract ICI
Blanchet B, Saboureau C, Benichou AS, Billemont B, Taieb F, Ropert S, Dauphin A, Goldwasser F, Tod M. Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin Chim Acta 2009 Jun 27;404(2):134-139. Abstract ICI
Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, Harcouet L, Ropert S, Dauphin A, Goldwasser F, Tod M.V alidation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 2009 May 1;49(4):1109-1114. Abstract ICI
Hulin A, Blanchet B, Audard V, Barau C, Furlan V, Durrbach A, Taïeb F, Lang P, Grimbert P, Tod M. Comparison of 3 estimation methods of mycophenolic acid AUC based on a limited sampling strategy in renal transplant patients. Ther Drug Monit 2009 Apr;31(2):224-232. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Fronton L, You B, Pollet-Villard M, FreyerG, Tod M, Colomban O, Golfier F, Girard P Population model of Human Chorionic Gonadotropin to predict resistance in low risk gestational trophoblastic neoplasia patients. PAGE 18 (2009) Abstr 1540
Gérard C, Bleyzac N, Girard P, Tranchand B, Freyer G, Bertrand Y, Tod M. Link between cyclosporin exposure in tissues and graft versus host disease in paediatric bone marrow transplantation: analysis by a PBPK model. PAGE 18 (2009) Abstr 1608
Gérard C, Bleyzac N, Girard P, Tranchand B, Freyer G, Bertrand Y, Tod M. Influence of cyclosporin infusion duration on efficacy in paediatric bone marrow transplantation: analysis by a PBPK model. PAGE 18 (2009) Abstr 1607
Paule I, Sassi H, Habibi A, Bachir D, Galactéros F, Girard P, Hulin A, Tod M. Population Pharmacokinetics and Pharmacodynamics of Hydroxyurea in Sickle Cell Anemia Patients, In Silico Comparison of Two Dosing Regimens. PAGE 18 (2009) Abstr 1582
Ribba B, Watkin E, Tod M, Girard P, You B, Tranchand B, Grenier E, Freyer G. Estimating the kinetic parameters of vascular tumor growth models to optimize anti-angiogenesis drugs delivery. PAGE 18 (2009) Abstr 1534
Sostelly A, Hénin E, You B, Girard P, Karlsson MO. Simultaneous modelling of PSA production in Prostatic Benign Hyperplasia (PBH) and prostatic adenocarcinoma patients treated by prostate surgery. PAGE 18 (2009) Abstr 1497
Ternant D, Hénin E, Cartron G, Tod M, Paintaud G, Girard P. Model-based optimization of rituximab dosing regimen in follicular non-Hogdkin lymphoma. PAGE 18 (2009) Abstr 1519
Fontanilles M, Pilleul F, Colomban O, Tranchand B, Schott AM, Chayvialle JA, Tod M. Modelization of bevacizumab effect on tumour perfusion assessed by Dynamic Contrast Enhanced Ultrasonography. PAGE 18 (2009) Abstr 1546
Abstracts ASCO (American Society of Clinical Oncology)
Boyle H, You B, Fronton L, Ribba B, Girard P, Tranchand B, Tod M, Coquelin H, Droz JP, Flechon A. Major prognostic value of modeled AUChCG-AFP, a dynamic kinetic marker characterizing tumor marker decline of nonseminomatous germ cell tumors (NSGCT) intermediate-poor-risk patients according to the IGCCCG. J Clin Oncol ASCO Annual Meeting Proceedings;2009 27:15s, suppl; abstr 5085.
B. Billemont, M. Hornecker, S. Ropert, B. Blanchet, J. Jais, P. Blanchard, J. Meric, J. Alexandre, M. Tod, F. Goldwasser. Correlation of sorafenib plasma concentrations and clinical toxicity: A prospective population pharmacodynamic and pharmacokinetic study. J Clin Oncol ASCO Annual Meeting Proceedings;2009 27, suppl;abstr e14585.
Articles
You B, Perrin P, Freyer G, Ruffion A, Tranchand B, Hénin E, Paparel P, Ribba B, Devonec M, Falandry C, Fournel C, Tod M, Girard P. Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy. Clin Biochem 2008;41(10-11):785-795. Abstract ICI
Paule I, Girard P, Tod M, Freyer G, Henin E, Tranchand B. Capecitabine dosage adaptation to prevent severe hand-and-foot syndrome: comparison of standard and model-based approaches. Fund Clin Pharmacol 2008;22(S64):14.
Tranchand B, Falandry C, You B, Girard P, Ribba B, Tod M, Freyer G. Pharmacology of anticancer drugs in the elderly: tools for dose-adjustment. Bull Cancer 2008;95:F27. Abstract ICI
Ribba B, You B, Girard P, Tranchand B, Trillet-Lenoir V, Freyer G. Mathematic modelization of cancer: a fulcrum from fundamental research to clinical research. Bull Cancer 2008;95:S60.
Paule I, Tod M, Tranchand B, Freyer G, Henin E, Girard P. Model-based dose adaptation of capecitabine in order to prevent severe hand-and-foot syndrome: in silico comparison with the classical method. Bull Cancer 2008;95:S68
Girard P, Dartois C, Michallet M, Henin E, Vermot-Desroches C, Tranchand B, Trillet-Lenoir V, Freyer G. Development of a pharmacokinetic-pharmacodynamic model of inolimomab in GVHD patients Bull Cancer 2008;95:S74
Blanchet B, Duvoux C, Costentin CE, Barrault C, Ghaleh B, Salvat A, Jouault H, Astier A, Tod M, Hulin A. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period. Ther Drug Monitor 2008;30(4):412-418. Abstract ICI
Hochane M, Blanchet B, Giraudier S, Tod M, Astier A, Tulliez M, Hulin A. Practical TDM of imatinib in chronic myeloid leukaemia. Fund Clin Pharmacol 2008;2(S436)2:89
Meille C, Iliadis A, Barbolosi D, Frances N, Freyer G. An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. J Pharmacokinet Pharmacodyn 2008 Dec;35(6):619-33. Abstract ICI
Tod M, Lagneau F, Jullien V, Mimoz O. A physiological model to evaluate drug kinetics in patients with hemorrhagic shock followed by fluid resuscitation. Pharm Res 2008;25(6):1431-1439. Abstract ICI
Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokin 2008;47(4):231-243. Abstract ICI
Dumaine V, Eyrolle L, Baixench MT, Paugam A, Larousserie F, Padoin C, Tod M, Salmon D. Successful treatment of prosthetic knee Candida glabrata infection with caspofungin combined with flucytosine. Int J Antimicrob Agents 2008;31(4):398-399.
Cassier PA, Chabaud S, Trillet-Lenoir V, Peaud PY, Tigaud JD, Cure H, Orfeuvre H, Salles B, Martin C, Jacquin JP, Agostini C, Guastalla JP, Perol D, Bachelot,T. A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat 2008;109(2):343-350. Abstract ICI
Seve P, Reiman T, Isaac S, Trillet-Lenoir V, Lafanechere L, Sawyer M, Dumontet C. Protein abundance of class III beta-tubulin but not Delta 2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Anticancer Res 2008;28(2B):1161-1167. Abstract ICI
Berger F, Bossard N, Chauvin F, Janier M, Marche P, Trillet-Lenoir V, Vasson MP, Zoulim F, Pauwels P. CLARA canceropole : A dynamic network oriented towards cancerology research to the patients benefit. Bull Cancer 2008,95:S3-S9
Schott AM, Raudrant D, Guastalla JP, Mathian B, Frappart L, Trillet-Lenoir V, Massardier J, Golfier F. Lyon coordination pilot plant of trophoblastic tumors. Bull Cancer 2008;95:S56
Heudel P, Romestaing P, Barbet N, Falandry C, You B, Glehen O, Freyer G. Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: The Lyon R-02-01 phase I trial. Clin Oncol 2008;20(5):369-374. Abstract ICI
Falandry C, You B, Morel-Soldner I, Bonnefoy M, Pujade-Lauraine E, Freyer G. Ovarian cancer in the elderly. Oncologie 2008;10(1):3-7
Boissel JP, Ribba B, Grenier E, Chapuisat G, Dronne MA. Modelling methodology in physiopathology. Progress Bioph Molecular Biol 2008;97(1):28-39. Abstract ICI
Billy F, Ol S, Morre-Trouithet H, Colin T, Bresch D, Ribba B, Grenier E. Multiscale mathematical model of tumoral angiogenesis and application of the efficiency analysis of anti-angiogenic treatments. Bull Cancer 2008;95:S65
Bekkal-Brikci F, Clairambault J, Ribba B, Perthame B. An age-and-cyclin-structured cell population model for healthy and tumoral tissues. J Math Biol 2008;57(1): 91-110. Abstract ICI
You B, Perrin P, Freyer G, Tranchand B, Ribba B, Henin E, Ruffion A, Trillet-Lenoir V, Girard P. A new approach: "PSA clearance" predicts biochemical relapse risk of patients with prostate cancer in the first month following radical prostatectomy. Fund Clin Pharmacol 2008;22(57S): 12
You B, Tranchand B, Girard P, Falandry C, Ribba B, Chabaud S, Souquet PJ, Court-Fortune I, Trillet-Lenoir V, Fournel C, Tod M, Freyer G. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: A multicentre study. Lung Cancer 2008 ;62(2) :261-272. Abstract ICI
Tranchand B, Falandry C, You B, Girard P, Ribba B, Freyer G. Pharmacologie des agents anticancéreux chez le sujet âgé : une aide à l’adaptation des doses. Bull Cancer 2008:95(Supplément FMC n° 8):F21-F27
Tranchand B, Chabaud S, Colomban O, Dussart S, Pérol D. Design of Clinical Trials in Oncology. Lettre du Pharmacologue 2008;22(3):98-110
Tod M. Evaluation of drugs in pediatrics using K-PD models: perspectives. Fundam Clin Pharmacol 2008 Dec;22(6):589-594. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Hénin E, Trillet-Lenoir V, Tranchand B, Tod M, Girard P. Patient compliance estimated from pharmacokinetic sample: application to Imatinib. PAGE 17 (2008) Abstr 1363
Paule I, Tod M, Hénin E, You B, Tranchand B, Freyer G, Girard P. Model-based dose adaptation of capecitabine for prevention of severe hand-and-foot syndrome: in silico comparison with the standard method. PAGE 17 (2008) Abstr 1260
Ribba B, Chatel K, Tod M, Girard P, Freyer G, Tranchand B. Monolix benefits from external modules to manage complex ODE: Illustration with a population analysis of Irinotecan and its metabolites. PAGE 17 (2008) Abstr 1367
Abstracts ASCO (American Society of Clinical Oncology)
You B, Girard P, Freyer G, Tranchand B, Ruffion A, Paparel P, Devonec M, Henin E, Tod M, Perrin P. A new concept: PSA clearance predicts biochemical relapse risk of patients with prostate cancer in the first month following radical prostatectomy. ASCO Genitourinary Cancers Symposium Proceedings;2008 26: (20S):94
You B, Michallet A, Salles G, Casasnovas O, Tilly H,. Ribrag V, Sebban C, Falandry C, Tranchand B, FreyerG. Major dispersion in etoposide systemic exposure in malignant lymphoma patients receiving BEAM high dose chemotherapy followed by ABMT: A multicentre study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). J Clin Oncol ASCO Annual Meeting Proceedings;2008 26: (20S):8537
Freyer G, Fumoleau P, You B, Isambert N, Chevalier P, Trillet Lenoir V. A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol ASCO Annual Meeting Proceedings;2008 26:14539
Isambert N, Freyer G, Zanetta S, Falandry C, Soussan Lazard K, Fumoleau P. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: Preliminary results. J Clin Oncol ASCO Annual Meeting Proceedings 2008;26:3599
Articles
Golfier F, Labrousse C, Frappart L Mathian B, Guastalla JP, Trillet-Lenoir V, Hajri T, Schott AM, Raudrant D. Evaluation of treatment relating to gestational trophoblastic tumor registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon from 1999 to 2005. Gynécologie Obstétrique et Fertilité 2007;35 (3):205-215. Abstract ICI
Theis D, Gilleron V, Schott AM, Seguret F, Trillet-Lenoir V. An overview of the 2001-2002 cancer activity in the 30 French Regional and University Hospitals, based on PMSI data. Bull Cancer 2007;94(10):915-922. Abstract ICI
Falandry C, Bonnefoy M, You B, Freyer G. Metastatic prostate cancer treatment in the elderly. Bull Cancer. 2007;94 Suppl FMC:F89-96. Abstract ICI
Joerger M, Huitema A, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers HGJ, Twelves C, Beijnen JH, Schellens JHM. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG. Clin Pharmacokin. 2007;46(12):1051-1068. Abstract ICI
Dartois C, Brendel K, Comets E, Laffont C, Laveille C, Tranchand B, Mentre F, Lemenuel-Diot A, Girard P. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Br J Clin Pharmacol 2007;64(5):603-612. Abstract ICI
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Fety R, Van der Vijgh WJ, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH. Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. Clin Cancer Res 2007;13(21):6410-6418. Abstract ICI
Berges A, Laporte S, Epinat M, Zufferey P, Alamartine E, Tranchand B, Decousus H, Mismetti P. PROPHRE.75 Study Group. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol 2007;64(4):428-438. Abstract ICI
Hénin E, You B, Tranchand B, Freyer G, Girard P. Issues of the study of patient compliance to treatment with oral anticancer chemotherapy: advantages of pharmacokinetic-pharmacodynamic modelisation. Thérapie 2007;62(2):77-85. Abstract ICI
Jacqmin P, Snoeck E, Van Schaick EA, Gieschke R, Pillai G, Steimer J-L, Girard P. Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K-PD Model. J Pharmacokin Pharmacodyn 2007; 34(1):57-85. Abstract ICI
Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, Girard P, Laffont CM, Mentre F. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46(3):221-234. Abstract ICI
Dartois C, Lemenuel-Diot A, Laveille C, Tranchand B, Tod M, Girard P. Evaluation of Uncertainty Parameters Estimated by Different Population PK Software and Methods. J Pharmacokinet Pharmacodyn 2007; 34(3):289-311. Abstract ICI
Testart-Paillet D, Girard P, You B, Freyer G, Pobel C, Tranchand B. Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Crit Rev Oncol Hematol 2007; 63:1-11. Abstract ICI
Dartois C, Freyer G, Michallet M, Hénin E, You B, Darlavoix I, Vermot-Desroches C, Tranchand B, Girard P. Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease. Clin Pharmacokinet 2007; 46(5):417-432. Abstract ICI
Gruwez B, Poirier MF, Dauphin A, Olie JP, Tod M. A kinetic-pharmacodynamic model for clinical trial simulation of antidepressant action: application to clomipramine-lithium interaction. Contemp Clin Trials 2007; 28(3):276-287. Abstract ICI
Lichtman SM, Wildiers H, Chatelut E, Stiers C, Budman D, Morrison V, Tranchand B, Shapira I, Aapro M. International Society of Geriatric Oncology (SIOG) Chemotherapy Taskforce: Evaluation of chemotherapy in older patients. An analysis of the medical literature. J Clin Oncol 2007; 25(14):1832-1843. Abstract ICI
Tredan O, Geay JF, Touzet S, Delva R, Weber B, Cretin J, Provencal J, Martin J, Stefani L, Pujade-Lauraine E, Freyer G. Groupe D'investigateurs Nationaux Pour l'étude Des Cancers Ovariens. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Ann Oncol 2007; 18(2):256-262. Abstract ICI
Tranchand B, Bruno R, Freyer G. Design of Phase I Studies in Oncology. In Ette EI and Williams PJ editors. Pharmacometrics: the Science of Quantitative Pharmacology. Wiley and Sons, Hoboken NJ USA, 2007
Abstracts PAGE (Population Approach Group in Europe)
You B, Perrin P, Paparel P, Freyer G, Colomban O, Tranchand B, Girard P. Kinetic models of PSA decrease after surgery in prostate tumor diseases as a help for clinician interpretation. PAGE 16 (2007) Abstr 1119
Ribba B, Tod M, Girard P, You B, Mercier C, Vassal G, Freyer G, Tranchand B. ODE solvers and stiffness issues for complex population PK models. PAGE 16 (2007) Abstr 1143
Delavenne X, Basset T, Girard P , Decousus H, Mismetti P, Laporte S. The use of an indirect response model to assess interaction between drugs: acenocoumarol and amoxicillin + clavulanic acid. PAGE 16 (2007) Abstr 1115
Hénin E, Trillet-Lenoir V, Colomban O, Tod M, Girard P. Estimation of patient compliance from pharmacokinetic samples. PAGE 16 (2007) Abstr 1193
Tod M, Blanchet B, Astier A, Hulin A. Steady-state Equation for the Bicompartmental Model with Gamma Absorption. Application to Mycophenolate PK in Renal Transplant Patients. PAGE 16 (2007) Abstr 1074
Abstracts ASCO (American Society of Clinical Oncology)
You B, Meille C, Barbolosi D, Tranchand B, Guitton J, Rioufol C, Iliadis A, Freyer G. A mechanistic model predicting hematopoiesis and tumor growth to optimize docetaxel + epirubicin (ET) administration in metastatic breast cancer (MBC): Phase I trial. J Clin Oncol ASCO Annual Meeting Proceedings;2007 25(18S):13013
Falandry C, You B, Milano G, Chatelut E, Rebischung C, Glehen O, Mille D, Delord J, Lledo G, Trillet-Lenoir V, Freyer G. Individual genotyping to optimize chemotherapy in metastatic colorectal cancer (MCRC): The COLOGEN trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings; 25(18S):2510
Articles
Gilly FN, Cotte E, Brigand C, Monneuse O, Beaujard AC, Freyer G, Glehen O. Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol 2006; 32(6):597-601. Abstract ICI
Salas S, Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Tranchand B, Monjanel-Mouterde S, Baciuchka-Palmaro M, Dupuis C, Yang C, Balti M, Lacarelle B, Duffaud F, Durand A, Favre R. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther Drug Monit 2006; 28(4):532-539. Abstract ICI
Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Duffaud F, Digue L, Tranchand B, Monjanel-Mouterde S, Guillet P, Nicoara A, Baciuchka M, Bagarry-Liegey D, Lacarelle B, Noble A, Durand A, Favre R. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities. Ther Drug Monit 2006; 28(2):212-218. Abstract ICI
Ribba B, Saut O, Colin T, Bresch D, Grenier E. Boissel JP. A multiscale mathematical model of a vascular tumor growth to predict the therapeutic bene.t of anti-invasive agents. J Theor Biol 2006; 243(4):532-541. Abstract ICI
Ribba B, Tracqui P, Boix JL, Boissel JP, Thomas SR. QxDB: A generic quantitative database to support mathematical modelling in biology. Phil Transact A Math Phys Eng Sci 2006; 364(1843):1517-1532. Abstract ICI
Ribba B, Colin T, Schnell S. A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies. Theor Biol Med Model 2006; 3:7. Abstract ICI
You B, Trillet-Lenoir V. Targeted therapies in oncology. Rev Med Interne. 2006 Dec;27S3:S285-S288
Boissel JP, Amsallem E, Kasparian C, Diallo M, Ribba B. Les traitements utilisés en cancérologie sont ils fondés sur des données de haut niveau de preuve ? Risque et Qualité, 2006 ; 3(2) :123-128
Freyer G, Braud AC, Vilela G, Zelek L. Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the “observatory on elderly patients”. Ann Oncol 2006; 17(2):211-216. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Brendel K, Dartois C, Comets E, Laveille C, Lemmenuel-Diot A, Tranchand B, Girard P, Laffont C, Mentré F. Are population PK/PD models adequately evaluated? An exhaustive survey of the literature between 2002 and 2004. PAGE 15 (2006) Abstr 1009
Dartois C, Brendel K, Comets E, Laveille C, Laffont C, Tranchand B, Mentré F, Lemenuel-Diot A, Girard P. How is model building reported for population PK-PD? An exhaustive survey of the literature between 2002 and 2004. PAGE 15 (2006) Abstr 998
Hénin E, Zuideveld KP, Dartois C, Tranchand B, Freyer G, Girard P. A KPD Model for ordered categorical data: application to toxicity score in colorectal cancer patients treated with capecitabine. PAGE 15 (2006) Abstr 929
Claret, L, Girard P, Zuideveld KP, Jorga K, Fagerberg J, Bruno R. A longitudinal model for tumor size measurements in clinical oncology studies. PAGE 15 (2006) Abstr 1004
Abstracts ASCO (American Society of Clinical Oncology)
Claret L, Girard P, O'Shaughnessy J, Hoff P, Van Cutsem E, Blum J, Zuideveld K, Jorga K, Fagerberg J, Bruno R. Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent. J Clin Oncol 2006 ASCO Annual Meeting Proceedings; 24(18S):6025
Salas S, Mercier C, Ciccolini J, Pourroy B, Dupuis C, Deville J, Baciuchka-Palmaro M, Durand A, Duffaud F, Tranchand B, Favre R. Population pharmacokinetic of total cisplatinum: Application to adaptative dosing with feed back in testicular cancer patient. J Clin Oncol 2006 ASCO Annual Meeting Proceedings; 24(18S):2043
Freyer G, Debled M, Geay JF, Bachelot T, Blot E, Cretin J, Delozier T, Mille D, Ferrero JM, Romestaing P, Pujade-Lauraine E. Celecoxib (Ce) + exemestane (Ex) versus placebo + Ex in post-menopausal (PM) metastatic breast cancer (MBC) patients (pts): A double-blind phase III GINECO study. J Clin Oncol 2006 ASCO Annual Meeting Proceedings; 24(18S):565
Articles
Guitton J, Cohen S, Tranchand B, Vignal B, Droz JP, Guillaumont M, Manchon M, Freyer G. Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19(17):2419-2426. Abstract ICI
Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP, Ganem G, Tubiana-Mathieu N, Gisserot O, Pujade-Lauraine E. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma. Ann Oncol 2005; 16(11):1795-1800. Abstract ICI
Girard P. Clinical trial simulation: a tool for understanding study failures and preventing them. Basic Clin Pharmacol Toxicol 2005; 96(3):228-234. Abstract ICI
Ribba B, Marron K, Agur Z, Alarcon T, Maini P. A mathematical model of Doxorubicin treatment efficacy on non-Hodgkin’s lymphoma: Investigation of current protocol through theoretical modelling result. Bull Math Biol 2005; 67(1):79-99. Abstract ICI
Gaujard S, Albrand G, Bonnefoy M, Courpron P, Freyer G. Le maniement des médicaments anticancéreux chez les malades âgés Press Med 2005 ; 34 :673-680. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Testart D, Girard P, Droz JP, Hénin E, Ardiet C, Zanetta S, Tranchand B. PK-PD model compared with K-PD model to predict haematotoxicity induced by anticancer drugs. PAGE 14 (2005) Abstr 695
Girard P, Mentré F. A comparison of estimation methods in nonlinear mixed effects models using a blind analysis. PAGE 14 (2005) Abstr 834
Bergès A, Laporte S, Girard P, Epinat M , Zufferey P, Alamartine E, Decousus H, Mismetti P, for the PROPHRE-75 study Group. Do we need a perfect basic structural model before exploring the covariate model? Example with enoxaparin. PAGE 14 (2005) Abstr 790
Gruwez B, Tod M, Dauphin A. mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol. PAGE 14 (2005) Abstr 698
Abstracts ASCO (American Society of Clinical Oncology)
Freyer G, Trédan O, Meille C, Barbolosi D, Tranchand B, Girard P, Iliadis A. Optimal duration of G-CSF prophylaxis after Docetaxel (D) + Epirubicin (E) in metastatic breast cancer (MBC): prediction using a mathematical model. J Clin Oncol 2005 ASCO Annual Meeting Proceedings; 23(16S):2044
Penault-Llorca F, Vincent-Salomon A, Mathieu MC, Trillet-Lenoir V, Khayat D, Marty M On Behalf Of The Esther Study Group. Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC). J Clin Oncol 2005 ASCO Annual Meeting Proceedings; 23(16S):764
http://www.ncbi.nlm.nih.gov/pubmed/16093275
Articles
Freyer G, Lortholary A, Delcambre C, Delozier T, Piot G, Genin F, Pujade-Lauraine E; Groupe D'investigateurs Nationaux Pour l’étude Des Cancers Ovariens. Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breastcancer: the Gineco experience. Clin Oncol (R Coll Radiol). 2004; 16(1):17-23. Abstract ICI
Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, Francois Y, Vignal J, Gilly FN. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004; 139(1):20-26. Abstract ICI
Girard P, Cucherat M, Guez D. Clinical trial simulation in drug development. Thérapie 2004; 59(3):287-304. Abstract ICI
Trillet-Lenoir V, Chapuis F, Touzet S, Barbier JY, Freyer G, Gaudin JL, Lombard-Bohas C, Vallet PJ, Lledo G, Gouttebel MC, Boyer JD, Chassignol L, Hamon H, Claudel-Bonvoisin S, Leprince E, Amoyal P, Glenhen O, Darnand P, Heilmann MO, Bleuse JP. Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas? Clin Oncol 2004; 16(3):196-203. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Dartois C, Laveille C, Tranchand B, Tod M, Girard P. What is the Value of Uncertainty Parameter Estimates provided by Different Population PK Methods? PAGE 13 (2004) Abstr 475
Articles
Gerard JP, Chapet O, Nemoz C, Romestaing P, Mornex F, Coquard R, Barbet N, Atlan D, Adeleine P, Freyer G. Preoperative Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer With High-Dose Radiation and Oxaliplatin-Containing Regimen: The Lyon R0-04 Phase II Trial. J Clin Oncol 2003; 21(6):1119-1124. Abstract ICI
Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003; 21(5):799-806. Abstract ICI
Sasco AJ, Merrill RM, Benhai M, Luzon V, Gerard , Freyer G. Trends in tobacco smoking among adolescents in Lyon, France. Eur J Cancer 2003; 39(4):496-504. Abstract ICI
Barbolosi D, Freyer G, Ciccolini J, Iliadis A. Dosage regimen optimization in cancer chemotherapy using a mathematical model. Bull Cancer 2003; 90(2):167-175. ICI
Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21(1):35-40. ICI
Dumontet C, Jaubert J, Sebban C, Bouafia F, Ardiet C,Tranchand B, Berger E, Lucas C, Guyotat D, Salles G, Coiffier B. Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. Ann Oncol 2003; 14(4), 615-622. Abstract ICI
Tranchand B, Laporte S, Glehen O, Freyer G. Pharmacology of cytotoxic agents: a helpful tool for building dose adjustment guidelines in the elderly.Crit Rev Oncol Hematol 2003; 48(2):199-214. Abstract ICI
Kastrissios H, Girard P. Protocol deviations and execution models. In: Ko HC, Duffull SB, editors. Simulation for Designing Clinical Trials. Marcel Dekker NY USA, 2003
Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, Trillet-lenoir V, Sayag-Beaujard AC, Francois Y, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003; 10(8): 863-869. ICI
Clippe C, Freyer G, Milano G, Trillet-Lenoir V. Lethal toxicity of capecitabine due to abusive folic acid prescription? Clin Oncol 2003; 15(5):299-300.
Jaisson-Hot I, Schott AM, Clippe C, Ganne C, Hajri T, Poncet B, Trillet-Lenoir V, Colin C. Méthodes d’évaluation médico-économique. Applications à la Cancérologie Bull Cancer 2003 ; 90(11):939-945
Ganne C, Trillet-Lenoir V, Jaisson-Hot I, Clippe C, Heilmann MO, Hajri T, Poncet B, Heuclin C, Colin C. Quelles approches médico-économiques choisir pour l’évaluation de l’impact des molécules coûteuses en cancérologie Le modèle de l’Herceptin? dans le cancer du sein métastatique. Bull Cancer 2003 ; 90(11):955-960
Clippe C, Trillet-Lenoir V, Freyer G. Treatment of cancer : surgery, radiotherapy, chemotherapy, hormonotherapy. Multidisciplinary therapeutic decision making and informing the patient. Rev Prat 2003; 53(2):187-198.Review
Etienne–Mastroianni B, Freyer G, Cordier JF. Secondary lung cancers. Rev Prat 2003; 53(7):756-759. Review. Abstract ICI
Freyer G. Pharmacocinétique de population et prédiction de la toxicité hématologique des chimiothérapies. Oncologie 2003; 5:18-23
Girard P, Claret L, Ebling WF, Forgue S, Heathman M, Ghosh A, Benson CT. Qualification of an osteoporosis biomarker model for simulation. Clin Pharmacol Ther 2003; 73[2], 85
Abstracts PAGE (Population Approach Group in Europe)
Chanu P, Janoly-Dumenil A, Bleyzac N, Bourgeois J, Tranchand B. Pharmacokinetic model for vancomycin performed with sparse data on neonates. PAGE 12 (2003) Abstr 363
Girard P, Claret L, Ebling W, Forgue ST, Heathman M, Ghosh A, Benson CT. Evaluation Of An Osteoporosis Biomarker Model For Simulation Using Posterior Predictive Check Technique. PAGE 12 (2003) Abstr 460
Bourhis Y, Iliadis A, Lucas C, Depouilly AB, Laveille C, Tranchand B. Population Pharmacokinetic Study of Fotemustine. PAGE 12 (2003) Abstr 407
Abstracts ASCO (American Society of Clinical Oncology)
Mercier C, Tranchand B, Sicard E, Santos A, Vernillet L, Pein F, Doz F, Frappaz D, Mery Mignard D, Vassal G. Population pharmacokinetics of CPT-11 and its main metabolites in children: A NONMEM and Xpose covariates analysis. Proc Am Soc Clin Oncol 2003;22:529
Articles
Trillet-Lenoir V, Freyer G, Kaemmerlen P, Fond A, Pellet O, Lombard-Bohas C, Gaudin JL, Lledo G, Mackiewicz R, Gouttebel MC, Moindrot H, Boyer JD, Chassignol L, Stremsdoerfer N, Desseigne F, Moreau JM, Hedelius F, Moraillon A, Chapuis F, Bleuse JP, Barbier Y, Heilmann MO, Valette PJ. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol 2002; 75(899):903-908. Abstract ICI
Trillet-Lenoir V, Piedbois P, Buyse M. The role of colony stimulating factors in small cell lung cancer: why the question is still unsolved. Lung Cancer 2002; 37(2):125-126.
Schott AM, Hajri T, Colin C, Grateau F, Gilly FN, Tissot E, Couchoud C, Morestin C, Trillet-Lenoir V. Usefulness of the French DRG based information system (PMSI) in the measurement of cancer activity in a multidisciplinary hospital: the Hospices Civils de Lyon. Bull Cancer 2002; 89(11):969-973. Abstract ICI
Clippe C, Ligneau B, Trillet-Lenoir V. Rôle de la Gemcitabine dans le traitement des tumeurs malignes Bull Cancer 2002 ; 89:S 120-122. Abstract ICI
Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer. 2002; 94(9):2434-2440. Abstract ICI
Omezzine N, Khouatra C, Larive S, Freyer G, Isaac-Pinet S, Geriniere L, Droz JP, Souquet PJ. Rhabdomyosarcoma arising in mediastinal teratoma in an adult man: a case report. Ann Oncol 2002; 13(2):323-326. Review. Abstract ICI
Trillet-Lenoir V. Un bon « RUM" vaut mieux que deux « tu l’auras ». Editorial. Bull Cancer 2002; 89(11):991
Lansac J, Trillet-Lenoir V. Qui fait quoi en cancérologie en France ? Quelques réponses du PMSI. Info en santé 2002; 3:6-7
Clippe C, Freyer G, Bizollon MH, Raudrant D, Gilly F, Vitrey D, Ligneau B, Trillet-Lenoir V. Tumeurs malignes primitives du péritoine : étude d’une série de huit cas et revue de la littérature. Bull Cancer 2002; 89(4):430-436. Abstract ICI
Bonadona V, Saltel P, Desseigne F, Mignotte H, Saurin JC, Wang Q, Sinilnikova O, Giraud S, Freyer G, Plauchu H, Puisieux A, Lasset C. Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and behavior after the disclosure of a positive test result. Cancer Epidemiol Biomarkers Prev 2002; 11(1):97-104. Abstract ICI
Freyer G, Hennebert P, Awada A, Gil T, Kerger J, Selleslags J, Brassinne C, Piccart M, De Valeriola D. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. Clin Cancer Res 2002; 8(1):95-102. Abstract ICI
Nguyen L, Tranchand B, Puozzo C, Variol P. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 2002; 53 (5):459-468. Abstract ICI
Variol P, Nguyen L, Tranchand B, Puozzo C. A simultaneous oral/iv population pharmacokinetic model for vinorelbine Eur J Clin Pharmacol 2002; 58:467-470. Abstract ICI
Vigneau C, Ardiet C, Bret M, Laville M, Fiere D, Tranchand B, Fouque D. Intermediate-dose (25mg/m²) IV melphalan for multiple myeloma with renal failure. J Nephrol 2002; 15(6):684-689. Abstract ICI
Chabaud S, Girard P, Nony P, Boissel JP. Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris. J Pharmacokinet Pharmacodyn 2002; 29(4):339-363. Abstract ICI
Chaulet JF, Nony P, Bevalot F, Girard P, Chabaud S, Mounier C, Clair P, Boissel JP, Grelaud G. Bioequivalence evaluation of a fixed combination of chloroquine and proguanil in a capsule formulation versus a standard medication. Arzneimittelforschung 2002; 52(5):407-412. Abstract ICI
Duval V, Chabaud S, Girard P, Cucherat M, Hommel M, Boissel JP. Physiologically based model of acute ischemic stroke. J Cereb Blood Flow Metab 2002; 22(8):1010-1018. Abstract ICI
Abstracts PAGE (Population Approach Group in Europe)
Tranchand B, Laporte S. Design and practical problems in population PK studies in the elderly. PAGE 11 (2002) Abstr 346
Chanu P, Tranchand B, Robert J. Population pharmacokinetics of epirubicin and its main metabolite epirubicinol using NONMEM. PAGE 11 (2002) Abstr 299
Hourcade-Potelleret F, Laveille C, Tod M, Jochemsen R. Mixture models: simulation and estimation with NONMEM. PAGE 11 (2002) Abstr 351
Tod M. Handling Concentrations Below Quantification Limit in Population. PAGE 11 (2002) Abstr 252
Abstracts ASCO (American Society of Clinical Oncology)
Freyer G, Le Rol A, Weber B, Provencal J, Ganem G, Jacquin J, Lavau-Denes S, Gisserot O, Flesch M, Paraiso D. GINECO Geriatric evaluation (GE) and feasibility of platin-based first-line chemotherapy in elderly patients with advanced ovarian cancer (AOC) Proc Am Soc Clin Oncol 2002; 21:1432
Gérard JP, Chapet O, Romestaing P, Mornex F, Coquard R, Barbet N, Atlan D, Freyer G. Oxaliplatin (OXA), fluorouracil (5-FU), I-leucovorin (I-LV) and radiotherapy (FolfoR 2) as preoperative treatment of advanced rectal cancer (ARC): the Lyon R0-04 phase II trial. Proc Am Soc Clin Oncol 2002; 21:581
Fumoleau P, Largillier R, Trillet-Lenoir V, Orfeuvre H, Extra JM, Dieras V, Berton-Rigaud D, Lesimple T, Culine S, Montestruc F, Mouri Z, Namer M. Capecitabine (Xeloda) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: results of a large phase II study. Proc Am Soc Clin Oncol 2002; 21:247
Thesis and Post-Doc
Ongoing Cécile Gérard Modèles PB-PK-PD de l'action des immunosupresseurs
Ongoing Inès Paule Adaptation de posologie des médicaments anticancéreux sur la base des modèles longitudinaux à effets mixtes
Ongoing Benoît You Dynamic analysis of serum tumor marker decline following anticancer treatment using population kinetic modeling approach
2009 David Ternant (Post doc) Development of a drug – disease simulation model for rituximab in follicular non-Hodgkin lymphoma
2008 Emilie Hénin Etude par la modélisation pharmacologique de la non-observance aux chimiothérapies anticancéreuses orales
2006 Céline DARTOIS Validation des modèles PK/PD de population utilisés en oncologie
2006 Cédric Mercier Apport de la pharmacologie de population pour l’adaptation des posologies en oncologie : application à 4 cytotoxiques
Master Reports
2010 Mélanie Wilbaux Etude toxico-génomique de la relation dose-expression du 1,3 Dinitrobenzène, et détermination de Benchmark Doses
2010 Guillaume Bonnefois Modélisation du pasage intracellulaire du sorafenib dans les cellules endothéliales
2010 Pierre Heudel Paramètres de la radiorésistance et leurs applications en modélisation pour les lignées tumorales gliales
2009 Maxime Fontanilles Modélisation de l’effet du bévacizumab sur les métastases hépatiques évalué par l’échographie dynamique de contraste
2009 Floriane Lignet Modélisation de l’action d’un médicament anti-angiogénique aux niveaux moléculaire et cellulaire
2009 Alexandre Sostelly Construction d’un modèle mécanistique pour la sécrétion, la distribution et l’élimination du PSA au cours de la phase de croissance et après prostatectomie radicale.
2008 Charlotte Castellan Développement de modèles physiologiques pharmacocinétiques pour la prédiction de la distribution tissulaire de la vindésine
2008 Taha Reda Lamnii Pharmacocinétique de l’irinotécan administré en chimiohyperthermie intrapéritonéale au cours du traitement des carcinoses péritonéales primitives et d’origine digestive
2008 Emmanuel Watkin PROJET SILICOLON: Optimisation in silico de la chimiothérapie dans le cancer colorectal métastatique Etude préliminaire: Mise en place des techniques anatomopathologiques de validation des modèles chez la souris nude xénogreffée
2007 Inès Paule Adaptation de la posologie de la capécitabine à l’aide d’un modèle longitudinal pour données catégorielles ordonnées
2007 Eddy Cotte Etude pharmacocinétique de la mitomycine C et du cisplatine au cours des chimiohyperthermies intrapéritonéales pour traitement des carcinoses péritonéales d’origine ovarienne, primitive ou digestive
2007 Benoît You Rôle pronostique de la cinétique de décroissance du PSA après prostatectomie radicale
2006 Olivier Colomban Modèles de toxicité de l’irinotécan (CPT-11) et recherche de la Dose Maximale Tolérée par la méthode de réévaluation en continu (C.R.M)
2005 Olivier Colomban Pharmacocinétique du Thiotépa administré à hautes doses chez l’enfant porteur de tumeurs réfractaires ou en rechute
2005 Diane Testart Modélisation de l’hématotoxicité induite par les chimiothérapies anticancéreuses : Modèle pharmacocinétique et K-PD
Internship Reports
2009 Cécile Gérard Prédiction de l’exposition tissulaire à la ciclosporine chez l’homme: utilisation d’un modèle physiologique
2007 Diane Testart Modélisation pharmacocinétique du méthotrexate et du docétaxel. Un premier pas vers la gestion des toxicités
